New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Team establishes positive clinical impact of the Multidisciplinary Molecular Tumor Board

Team establishes positive clinical impact of the Multidisciplinary Molecular Tumor Board

byThe University of Hong KongCredit: Unsplash/CC0 Public DomainA collaborative group led by the Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, the Univers
Oncology January 08,2024
Team establishes positive clinical impact of the Multidisciplinary Molecular Tumor Board

Team establishes positive clinical impact of the Multidisciplinary Molecular Tumor Board

byThe University of Hong KongCredit: Unsplash/CC0 Public DomainA collaborative group led by the Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, the Univers
Oncology January 08,2024
Team establishes a large collection of cholangiocarcinoma models for preclinical drug evaluation and biomarker discovery

Team establishes a large collection of cholangiocarcinoma models for preclinical drug evaluation and biomarker discovery

by Vall d'Hebron Institute of OncologyCholangiocarcinomas (CCAs) are a highly aggressive and diverse group of malignancies of the biliary tract that currently account for 15% of all liver cancers
Oncology January 08,2024
Team establishes a large collection of cholangiocarcinoma models for preclinical drug evaluation and biomarker discovery

Team establishes a large collection of cholangiocarcinoma models for preclinical drug evaluation and biomarker discovery

by Vall d'Hebron Institute of OncologyCholangiocarcinomas (CCAs) are a highly aggressive and diverse group of malignancies of the biliary tract that currently account for 15% of all liver cancers
Oncology January 08,2024
Team publishes new study on murine model for human early/immature T-cell precursor acute lymphoblastic leukemia

Team publishes new study on murine model for human early/immature T-cell precursor acute lymphoblastic leukemia

by Impact Journals LLCFigure 1 (truncated): Idh2R140Q/NHD13 double transgenic mice develop EITP ALL resembling the human disease. Credit: 2022 Negi and AplanA new research perspective titled "A m
Oncology January 07,2024
Team publishes new study on murine model for human early/immature T-cell precursor acute lymphoblastic leukemia

Team publishes new study on murine model for human early/immature T-cell precursor acute lymphoblastic leukemia

by Impact Journals LLCFigure 1 (truncated): Idh2R140Q/NHD13 double transgenic mice develop EITP ALL resembling the human disease. Credit: 2022 Negi and AplanA new research perspective titled "A m
Oncology January 07,2024
Team successfully generates mouse models for two subtypes of multiple myeloma

Team successfully generates mouse models for two subtypes of multiple myeloma

by Catarina Pietschmann,Max Delbrück Center for Molecular MedicineLeft: Normal bone marrow in the control animals with stained myeloid cells. Right: Bone marrow in the transgenic animals with pl
Oncology January 07,2024
Team successfully generates mouse models for two subtypes of multiple myeloma

Team successfully generates mouse models for two subtypes of multiple myeloma

by Catarina Pietschmann,Max Delbrück Center for Molecular MedicineLeft: Normal bone marrow in the control animals with stained myeloid cells. Right: Bone marrow in the transgenic animals with pl
Oncology January 07,2024
Team reports on development of potential new generic treatment for multiple types of cancer

Team reports on development of potential new generic treatment for multiple types of cancer

byRIKENA schematic of the study. The simple targeted alpha-particle therapy (TAT) compound was made by joining the radionuclide astatine-211 to an azide. The TAT compound was injected into a mic
Oncology January 07,2024
Team reports on development of potential new generic treatment for multiple types of cancer

Team reports on development of potential new generic treatment for multiple types of cancer

byRIKENA schematic of the study. The simple targeted alpha-particle therapy (TAT) compound was made by joining the radionuclide astatine-211 to an azide. The TAT compound was injected into a mic
Oncology January 07,2024
Image-guided adaptive radiation treatments reduce short-term side effects for patients with prostate cancer

Image-guided adaptive radiation treatments reduce short-term side effects for patients with prostate cancer

byWileyCredit: Pixabay/CC0 Public DomainA technique that uses imaging technology as a guide can make radiation therapy safer for patients with prostate cancer by helping clinicians accurately ai
Oncology January 07,2024
Image-guided adaptive radiation treatments reduce short-term side effects for patients with prostate cancer

Image-guided adaptive radiation treatments reduce short-term side effects for patients with prostate cancer

byWileyCredit: Pixabay/CC0 Public DomainA technique that uses imaging technology as a guide can make radiation therapy safer for patients with prostate cancer by helping clinicians accurately ai
Oncology January 07,2024
Breakthrough brings potential glioblastoma drug into focus

Breakthrough brings potential glioblastoma drug into focus

byKeck School of Medicine of USCA new type of small molecule drug, the first to target circadian clock proteins as a way to treat glioblastoma, is now in phase 1 clinical trials. Credit: Issey T
Oncology January 07,2024
Breakthrough brings potential glioblastoma drug into focus

Breakthrough brings potential glioblastoma drug into focus

byKeck School of Medicine of USCA new type of small molecule drug, the first to target circadian clock proteins as a way to treat glioblastoma, is now in phase 1 clinical trials. Credit: Issey T
Oncology January 07,2024
Treatment strategies for adenoid cystic carcinoma of the head and neck

Treatment strategies for adenoid cystic carcinoma of the head and neck

by Impact Journals LLCCT-scan in a coronal section showing an adenoid cystic carcinoma as an inhomogeneous mass in the rightmaxillary sinus with infiltration of neighboring structures. Credit: 2023 Du
Oncology January 07,2024
Treatment strategies for adenoid cystic carcinoma of the head and neck

Treatment strategies for adenoid cystic carcinoma of the head and neck

by Impact Journals LLCCT-scan in a coronal section showing an adenoid cystic carcinoma as an inhomogeneous mass in the rightmaxillary sinus with infiltration of neighboring structures. Credit: 2023 Du
Oncology January 07,2024
Uncontrolled heart risk factors common in head, neck squamous cell cancer

Uncontrolled heart risk factors common in head, neck squamous cell cancer

by Elana GotkineThe burden of suboptimally controlled cardiovascular (CV) risk factors and incident risk of stroke and myocardial infarction (MI) are considerable in patients with head and neck squamo
Oncology January 07,2024
Uncontrolled heart risk factors common in head, neck squamous cell cancer

Uncontrolled heart risk factors common in head, neck squamous cell cancer

by Elana GotkineThe burden of suboptimally controlled cardiovascular (CV) risk factors and incident risk of stroke and myocardial infarction (MI) are considerable in patients with head and neck squamo
Oncology January 07,2024
Head and neck cancer researchers demonstrate the capability of a deep learning algorithm in the post-surgery setting

Head and neck cancer researchers demonstrate the capability of a deep learning algorithm in the post-surgery setting

by ECOG-ACRIN Cancer Research Group"This type of research is key since it can help identify patients with high-risk, aggressive head and neck cancer, and also help select appropriate patients for
Oncology January 07,2024
Head and neck cancer researchers demonstrate the capability of a deep learning algorithm in the post-surgery setting

Head and neck cancer researchers demonstrate the capability of a deep learning algorithm in the post-surgery setting

by ECOG-ACRIN Cancer Research Group"This type of research is key since it can help identify patients with high-risk, aggressive head and neck cancer, and also help select appropriate patients for
Oncology January 07,2024
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com